A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Michael Unterhalt, Hermann Einsele(Universitätsklinikum Würzburg), Marcel Reiser(Rheinische Hochschule Köln), Hanneke C. Kluin‐Nelemans(University Medical Center Groningen), Martin Dreyling(LMU Klinikum), Hartmut Eimermacher(St. Marien Hospital), Wolfram Jung(University of Göttingen), Wolfgang Ludwig(Centre National de la Recherche Scientifique), Ulrich Dührsen(Essen University Hospital), Joerg Hasford(Ludwig-Maximilians-Universität München), Christian Gisselbrecht(Institut Universitaire de France), Achiel Van Hoof(AZ Sint-Jan), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Hannes Wandt(Nuremberg Hospital), Norma Peter(Carl-Thiem-Klinikum Cottbus), Bernd Metzner(Klinikum Oldenburg), Bernhard Wörmann(Charité - Universitätsmedizin Berlin), Michael Pfreundschuh(Saarland University)
Cited by 971
Related Papers
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820